The study of how differences in metabolites in an individual or subset of the population might be used to predict their various responses to a medicine or medical intervention is known as pharmacometabolomics or pharmacometabonomics. The premise that an individual's metabolic profile is related to their health-to-disease status, referred to as their "metabotype," is at the centre of pharmacometabolomics. Pharmacometabolomics data can help understand different drug responses (i.e. responders vs non-responders), be used in precision medicine to determine drug dose levels or specific drugs to prescribe for an individual, provide biomarkers related to drug efficacy or toxicity effects, and, in many cases, provide pharmacokinetics information, making pharmacometabolomics useful for precision medicine. Pharmacometabolomics can be used to tailor treatment type, dose, and duration, as well as to track metabolite profiles during treatments. Existing '-omics' and health-record databases, as well as biobanks of human fluid samples and tissues, are valuable resources for pharmacometabolomics, which seeks to uncover biomarkers of therapeutic effects across the course of a disease.